Wilson disease Flashcards
Prevalence of wilson
1 in 30,000
Percentage of pts with kayser fleischer rings
95%, all neuro patients,
-50% of liver patients
-presymptomatic 20-30%
Most common neuro symptoms
-dysarthria 46-97%
-dystonia 38-69%
-Tremor 55%
-Parkinsonism
-Dysphagia (50%)
-gait abnormality 28-75%
24 hr urine copper measurement
> 100 mcg in 75% of pts
Copper intake goal in wilson
< 1.0 mg/day
Name of ultragenyx trial
UX701
Cyprus
UX701 Stage 1 breakdown
OPEN LABEL (dose selection)
Cohort 1: gene therapy + prednisone (n=5)
Cohort 2: gene therapy dose 2 + prednisone (n=5)
Cohort 3: gene therapy dose 3 + prednisone (n=5)
Follow up to 52 weeks
UX701 Stage 2 Breakdown
DOUBLE BLIND, PLACEBO CONTROLLED
Cohort 1: Gene therapy (dose determined in stage1 ) + prednisone (n=42)
Cohort 2: Placebo (n=21)
UX701 Stage 3 breakdown
Cohort 1: pts that originally received placebo will receive gene therapy + prednisone at stage 2 dose
Cohort 2: pts originally that got gene therapy will get placebo
Age cutoff of UX701
18+
Inclusion criteria of UX701
-confirmed diagnosis of wilson
-ongoing copper chelator and or zinc therapy for at least 12 months (no dose or med change for at least 6 months)
-ongoing copper restricted diet for at least 12 months–stable lab values
Normal copper movement in cell
-CTR (copper transporter) brings copper into hepatocyte
-ATP7b transports copper to golgi apparatus
-ceruloplasmin binds to copper
-ceruloplasmin + copper vesicles released into bile and excreted, some released into blood
Percentage of patients with low ceruloplasmin
> 90%, usually less than 20
<5 is fairly diagnostic
Name of diagnostic scoring system
Leipzig score = >4
How does zinc work?
Increases metallothionine (protein in gut) that binds copper and decreases absorption in Gi tract